Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
Celanese Announces Commercial Launch of Glaukos' iDose® TR
DALLAS--(BUSINESS WIRE)--Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced that it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR, a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. iDose TR is designed to address patient non-adherence and chronic side effects associated with topical medications by providing 24/7, long-duration therapy. Glaukos submitted a New Drug Application to the U.S. Food and Drug Administration for iDose TR in February 2023, which has not yet been approved. nn“The inclusion of our VitalDose® Platform in Glaukos’ iDose TR therapy furthers our mission to improve patient health in ophthalmology for those living with chronic eye diseases” nnTweet this nSustained delivery of therapeutics has become an increasingly important approach to treating glaucoma. With the VitalDose® Drug Delivery Platform, there is now the potential to provide continuous dosing which can reduce patient compliance and adherence issues. nn“The inclusion of our VitalDose® Platform in Glaukos’ iDose TR therapy furthers our mission to improve patient health in ophthalmology for those living with chronic eye diseases,” says Cyonna Holmes, global business strategy leader for ophthalmology at Celanese. “Our team is excited to support Glaukos as they continue to advance their efforts to bring iDose TR to patients who may need a new glaucoma treatment alternative.” nnThe VitalDose® Drug Delivery Platform provides reliable, controlled-release performance and has a long history of use in approved parenteral drug products in the United States and Europe. For more information on Celanese VitalDose technology, visit
Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments
Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Space
Celanese Corporation, a global chemical and specialty materials company, announced an investment in expanded capabilities to meet high global demand for pharmaceutical-grade polymers used in the development of implants and inserts for sustained-release drug delivery.
DALLAS & EDMONTON, Alberta--(BUSINESS WIRE)--Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today announced an investment in expanded capabilities to meet high global demand for pharmaceutical-grade polymers used in the development of implants and inserts for sustained-release drug delivery. The new 1,000-square-foot cleanroom facility, located in Edmonton, Alberta, will focus on cryogenic micronization of VitalDose® EVA material into a powder form that is ready to be blended with small molecules and biologics.
Celanese Corporation, a global chemical and specialty materials company, announced receipt of a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant. The research and development will be conducted within the Celanese Pharmaceutical Development and Feasibility Lab and the project is expected to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
AURORA, Ontario & DALLAS--(BUSINESS WIRE)--Ovensa Inc. (“Ovensa”), a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, today announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the market.
Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today announced an expansion of its Florence, Kentucky research and development center with the addition of a Pharmaceutical Drug Delivery Feasibility Lab. The new feasibility lab will drive new development for long-acting controlled release drug delivery. This represents a significant investment and commitment to the Pharmaceutical segment of Celanese’s engineered materials business. The feasibility lab expands pharmaceutical companies’ access to highly customized materials and service solutions.